Literature DB >> 30108778

Identification of mitoxantrone as a new inhibitor of ROS1 fusion protein in non-small cell lung cancer cells.

Lian-Xiang Luo1, Xing-Xing Fan1, Ying Li1, Xia Peng2, Yin-Chun Ji2, Wendy Wen-Luan Hsiao1, Liang Liu1, Elaine Lai-Han Leung1, Xiao-Jun Yao1.   

Abstract

Mitoxantrone, an FDA-approved drug for multiple sclerosis and hormone refractory prostate cancer, is identified as a potent inhibitor of ROS1 fusion protein by in silico screening in non-small cell lung cancer cells. Mitoxantrone can suppress the phosphorylation of ROS1 and subsequently inhibit its downstream signaling pathway and thus induce cell apoptosis.

Entities:  

Year:  2017        PMID： 30108778      PMCID： PMC6071735          DOI： 10.1039/c6md00643d

Source DB:  PubMed          Journal:  Medchemcomm        ISSN： 2040-2503            Impact factor:   3.597


  21 in total

1.  Crizotinib.

Authors:  Alice T Shaw; Uma Yasothan; Peter Kirkpatrick
Journal:  Nat Rev Drug Discov       Date:  2011-12-01       Impact factor: 84.694

Review 2.  Drug-repositioning opportunities for cancer therapy: novel molecular targets for known compounds.

Authors:  Roberto Würth; Stefano Thellung; Adriana Bajetto; Michele Mazzanti; Tullio Florio; Federica Barbieri
Journal:  Drug Discov Today       Date:  2015-10-09       Impact factor: 7.851

3.  Crizotinib in ROS1-rearranged non-small-cell lung cancer.

Authors:  Alice T Shaw; Sai-Hong I Ou; Yung-Jue Bang; D Ross Camidge; Benjamin J Solomon; Ravi Salgia; Gregory J Riely; Marileila Varella-Garcia; Geoffrey I Shapiro; Daniel B Costa; Robert C Doebele; Long Phi Le; Zongli Zheng; Weiwei Tan; Patricia Stephenson; S Martin Shreeve; Lesley M Tye; James G Christensen; Keith D Wilner; Jeffrey W Clark; A John Iafrate
Journal:  N Engl J Med       Date:  2014-09-27       Impact factor: 91.245

4.  A new target for an old drug: identifying mitoxantrone as a nanomolar inhibitor of PIM1 kinase via kinome-wide selectivity modeling.

Authors:  Xiaobo Wan; Wei Zhang; Li Li; Yuting Xie; Wei Li; Niu Huang
Journal:  J Med Chem       Date:  2013-03-15       Impact factor: 7.446

5.  Can you teach old drugs new tricks?

Authors:  Nicola Nosengo
Journal:  Nature       Date:  2016-06-16       Impact factor: 49.962

6.  Escaping ALK inhibition: mechanisms of and strategies to overcome resistance.

Authors:  Christine M Lovly; William Pao
Journal:  Sci Transl Med       Date:  2012-02-08       Impact factor: 17.956

7.  Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins.

Authors:  Monika A Davare; Anna Saborowski; Christopher A Eide; Cristina Tognon; Rebecca L Smith; Johannes Elferich; Anupriya Agarwal; Jeffrey W Tyner; Ujwal P Shinde; Scott W Lowe; Brian J Druker
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-11       Impact factor: 11.205

Review 8.  Molecular pathways: ROS1 fusion proteins in cancer.

Authors:  Kurtis D Davies; Robert C Doebele
Journal:  Clin Cancer Res       Date:  2013-05-29       Impact factor: 12.531

9.  RET, ROS1 and ALK fusions in lung cancer.

Authors:  Kengo Takeuchi; Manabu Soda; Yuki Togashi; Ritsuro Suzuki; Seiji Sakata; Satoko Hatano; Reimi Asaka; Wakako Hamanaka; Hironori Ninomiya; Hirofumi Uehara; Young Lim Choi; Yukitoshi Satoh; Sakae Okumura; Ken Nakagawa; Hiroyuki Mano; Yuichi Ishikawa
Journal:  Nat Med       Date:  2012-02-12       Impact factor: 53.440

10.  Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity.

Authors:  Ricardo Sant'Anna; Pablo Gallego; Lei Z Robinson; Alda Pereira-Henriques; Nelson Ferreira; Francisca Pinheiro; Sebastian Esperante; Irantzu Pallares; Oscar Huertas; Maria Rosário Almeida; Natàlia Reixach; Raul Insa; Adrian Velazquez-Campoy; David Reverter; Núria Reig; Salvador Ventura
Journal:  Nat Commun       Date:  2016-02-23       Impact factor: 14.919
View more
  1 in total

1.  Identification of Flavonoids as Putative ROS-1 Kinase Inhibitors Using Pharmacophore Modeling for NSCLC Therapeutics.

Authors:  Shraddha Parate; Vikas Kumar; Jong Chan Hong; Keun Woo Lee
Journal:  Molecules       Date:  2021-04-07       Impact factor: 4.411
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.